Фармсинтез
Underestimation
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| P/E |
0/10
|
-2.14 | 10.89 | -119.67% | -4.62 | -53.68% |
| P/S |
|
1.89 | 1.43 | 32.02% |
|
|
| P/BV |
|
2.64 | 30.67 | -91.41% |
|
|
| P/FCF |
|
-1.74 | 6.85 | -125.37% |
|
|
| Ev/Ebitda |
|
-3.94 | 6.26 | -163.01% |
|
|
| Ev/S |
|
2.51 | 1.62 | 54.6% |
|
|
| Ev/FCF |
|
-2.31 | 7 | -132.93% |
|
|
| E/P |
|
-0.467 | 0.1086 | -529.86% |
|
|
Efficiency
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| Ebitda margin |
0/10
|
-63.66 | 24.17 | -363.37% | -66.01 | -3.55% |
| ROE |
|
-47.5 | 130.18 | -136.49% |
|
|
| ROA |
|
-17.67 | 11.14 | -258.59% |
|
|
| ROIC |
|
-49.48 | 14.31 | -445.77% |
|
|
| ROS |
|
-88.37 | 14.06 | -728.52% |
|
|
| ROCE |
|
0 | 2.83 | -100% |
|
|
Debt
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| Debt/Ebitda |
10/10
|
-2.15 | 1.62 | -232.1% | -2.44 | -12% |
| Nеt Debt/Ebitda |
|
-0.9726 | 1.06 | -191.5% |
|
|
| Debt/Ratio |
|
0.2733 | 0.3274 | -16.53% |
|
|
| Debt/Equity |
|
0.7344 | 4.15 | -82.31% |
|
|
| Debt/Net Income |
|
-1.55 | 3.82 | -140.42% |
|
|
Dividends
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| Dividend yield |
0/10
|
0 | 9.08 | -100% | 0 | 0% |
| Number of years of dividend growth |
|
0 | 0.6 | -100% | ||
| DSI |
|
0 | 0.3619 | -100% |
|
|
| Average dividend growth |
|
0 | -5.9 | -100% |
|
|
| Average percentage for 5 years |
|
0 | 4.96 | -100% |
|
|
| Average percentage for payments |
|
0 | 46.2 | -100% |
|
|
| Difference from average difference in sector |
|
-9.08 |
Growth impulse
| Parameter | Grade | Value | Sector average | Difference with sector, % | ||
|---|---|---|---|---|---|---|
| Growth impulse Revenue in 5 years |
10/10
|
223.12 | 322.95 | -30.91% | ||
| Growth impulse Ebitda in 5 years |
|
-69.91 | 100.93 | -169.27% | ||
| Growth impulse Net Income in 5 years |
|
-59.97 | 251.81 | -123.82% | ||
| Growth impulse FCF in 5 years |
|
407.27 | -135.74 | -400.04% | ||
| Growth impulse EPS in 5 years |
|
-72.64 | 47.39 | -253.28% |
IP Score
3.76/10
